DNA Drug Developer Seawolf Launches with $100 Million Funding and $1.2 Billion Sanofi Deal

A colourful illustration of a DNA double helix. Photo: National Human Genome Research Institute / Wikimedia Commons (Public domain)

Seawolf Therapeutics has launched publicly with $100 million in Series A funding and a collaboration with French drugmaker Sanofi worth up to $1.2 billion, as it seeks to develop a new class of DNA-based medicines.

The financing was backed by Versant Ventures, MPM BioImpact and Novartis Venture Fund, with Eli Lilly and CRISPR Therapeutics among the other participants. Under the Sanofi agreement, the two companies will work together on treatments for bleeding disorders and other conditions that have not been disclosed. Seawolf stands to receive milestone payments and royalties, as well as an upfront payment whose size its chief executive, Elizabeth Alcamo, declined to reveal.

The company’s technology, called TRIDENT, uses tiny fat particles to carry DNA into the nucleus of cells, without the viruses that existing gene therapies rely on to deliver their cargo. Seawolf says the approach could produce longer-lasting effects than RNA medicines and allow medicines to be given repeatedly, an option that virus-based gene therapies do not offer. Those claims are the company’s own and have not yet been tested in people.

Its lead programme, which has so far been tested only in animals, aims to build muscle and reduce fat, with possible uses in obesity, muscle loss and osteoporosis. Seawolf expects to select a drug candidate by late 2027 and to file for permission to begin human trials by the end of 2028. Alcamo said the company would probably need to raise additional capital to reach that stage.

The launch is the latest sign of investor appetite for genetic medicines that go beyond the first generation of virus-delivered gene therapies, even as the field faces hard questions about cost, durability and safety. For Seawolf, the test will be whether a technology that has worked in animals can be shown to work safely in humans, and whether the Sanofi partnership can turn an early-stage platform into approved treatments.

Note: this story is single-sourced from Reuters, and the claims about longer-lasting effects and repeat dosing are Seawolf’s own, unproven in humans.

Sources: Reuters, “DNA drug developer Seawolf launches with $100 million funding, Sanofi deal” (https://www.reuters.com/legal/litigation/dna-drug-developer-seawolf-launches-with-100-million-funding-sanofi-deal-2026-11-16/)

Leave a Reply

Your email address will not be published. Required fields are marked *